Verily planning comprehensive, high-tech campus for opioid addiction rehab and research

Addiction
The future campus aims to include clinical services, housing, vocational training and mixed-use business development. (Getty/BackyardProduction)

Verily has set its sights on building a high-tech rehabilitation center that will explore, evaluate and validate different models for responding to the opioid crisis.

To be based in Dayton, Ohio, Alphabet’s life sciences arm teamed up with two local health providers to build what it described as a nonprofit “learning health system” focused on addiction medicine.

“Beyond providing the technical infrastructure to treat patients day-to-day, the system will also generate insights that could advance the understanding of how to treat and promote sustained recovery for those experiencing addiction and allow for evolving best practices,” wrote Danielle Schlosser, a senior clinical scientist in behavioral health, in a Verily blog post.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

The goal is to create a campus that includes clinical services and housing, as well as businesses and mixed-use development open to patients and the local community. Verily also said it plans to invest in revitalizing the surrounding neighborhood.

RELATED: Verily pockets $1B with eyes on partnerships, M&A

Titled OneFifteen, the venture was launched with healthcare providers Kettering Health Network and Premier Health, and in partnership with Alexandria Real Estate Equities. It will be helmed by Marti Taylor, former CEO of University Hospital and the Ross Heart Hospital at The Ohio State University Wexner Medical Center.

“People living with addiction need multidimensional and easy-to-access treatment,” Schlosser wrote. “We recognize that if the full continuum of care as well as other services like recovery housing and vocational training could be in one location, it could produce better outcomes for patients and their loved ones.”

At the top of this year, Verily announced a $1 billion funding round for it to undertake new projects, partnerships and potential acquisitions. Verily’s CEO, Andrew Conrad, said he hopes the fundraising will allow the company to better position itself in evidence generation, as well as in value-based reimbursement care models.

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.